Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany.
Clin Exp Rheumatol. 2009 Jul-Aug;27(4 Suppl 55):S33-5.
Although both rheumatoid arthritis (RA) and ankyosing spondylitis (AS) belong to the group of chronic inflammatory rheumatic diseases, they are quite different regarding mechanisms of inflammation and repair. While RA is an erosive destructive disease with the synovium as the primary site of inflammation, the immune response in AS takes place primarily at the cartilage/bone interface, and the pathological but also the clinical picture is determined by an until not yet well defined interaction between inflammation and new bone formation. Most recently, first insights into the molecular mechanisms between inflammation and bone destruction or new bone formation could be obtained. Key molecules involved in bone homeostasis seem to differ between RA and AS patients. While the molecules sclerostin and dickkopf 1, both inhibitors of osteoblasts, are elevated in RA they are found to be rather low in AS. It can be expected that the rapidly expanding new field of osteoimmunology will help to clarify the pathogenesis of the these two diseases with possible implications for new treatment targets.
虽然类风湿关节炎(RA)和强直性脊柱炎(AS)都属于慢性炎症性风湿病,但它们在炎症和修复机制方面存在很大差异。RA 是一种侵蚀性破坏性疾病,以滑膜为主要炎症部位,而 AS 中的免疫反应主要发生在软骨/骨界面,其病理表现和临床表现主要由炎症和新骨形成之间尚未明确的相互作用决定。最近,人们对炎症和骨破坏或新骨形成之间的分子机制有了初步的了解。参与骨稳态的关键分子似乎在 RA 和 AS 患者之间存在差异。虽然 RA 患者中骨形成抑制剂骨硬化素和 Dickkopf 1 升高,但在 AS 患者中它们的水平较低。预计骨免疫学这一快速发展的新领域将有助于阐明这两种疾病的发病机制,为新的治疗靶点提供可能的依据。